Global prevalence, mortality, and main risk factors for COVID-19 associated pneumocystosis: A systematic review and meta-analysis

Objective: Pneumocystis pneumonia (PcP) is a life-threatening infection caused by the opportunistic fungi Pneumocystis jirovecii. The emergence of the COVID-19 pandemic forced the focus of attention of health policymakers on these two infections due to their clinical and paraclinical similarities, which cause diagnostic dilemmas. This study was undertaken to evaluate and estimate the global prevalence and main leading risk factors of coronavirus-associated pneumocystosis (CAP). Methods: We searched related databases between December 2019 and May 2022 for studies reporting CAP. Meta-analysis was performed using StatsDirect software (version 2.7.9) according to the DerSimonian and Laird method applying the random-effects model. We evaluated heterogeneity using the χ2-based Q statistic (significant for P<0.05) and the I2 statistic (>75% indicative of “notable” heterogeneity). Moreover, an odds ratio (OR) analysis was performed for eligible data. Results: Our meta-analysis included eight studies with 923 patients hospitalized with COVID-19; among them, 92 were PcP cases. The overall pooled prevalence of CAP was estimated at 11.5%. The mortality among CAP patients was lower than that of non-PcP patients (OR 1.93; 95% CI 0.86-4.31). Long-term corticosteroid therapy (OR 28.22; 95% CI 0.54-1 480.84) was the most predisposing factor for PcP among COVID-19 patients, followed by pulmonary diseases (OR 1.46; 95% CI 0.43-4.98), kidney diseases (OR 1.26; 95% CI 0.21-7.49), and acute respiratory destruction syndrome (OR1.22; 95% CI 0.05-29.28). Conclusions: The prevalence of PcP among the COVID-19 population is almost similar to the pre-COVID era. However, PcP-related mortality was decreased by the emergence of the COVID-19 pandemic. Women with COVID-19 are more susceptible to PcP than men. Acute respiratory distress syndrome, kidney diseases, pulmonary diseases, and long-term corticosteroid therapy increased the risk of PcP; however, transplantation and malignancy decreased the risk for PcP among COVID-19 patients. Further retrospective, case-control, prospective, and more precisely systematic review and meta-analysis studies are needed in this field.

[1]  H. Badali,et al.  Global prevalence and subgroup analyses of coronavirus disease (COVID‐19) associated Candida auris infections (CACa): A systematic review and meta‐analysis , 2022, Mycoses.

[2]  F. Noorbakhsh,et al.  SARS-CoV-2 spike protein displays sequence similarities with paramyxovirus surface proteins; a bioinformatics study , 2021, PloS one.

[3]  E. Yakovleva,et al.  Comparative study of the serum hepcidin level of patients with pneumonia in COVID-19 and Pneumocystis pneumonia. , 2021, Klinicheskaia laboratornaia diagnostika.

[4]  N. Chauhan,et al.  A systematic review on SARS‐CoV‐2‐associated fungal coinfections , 2021, Journal of medical virology.

[5]  J. Tran van Nhieu,et al.  Pneumocystis pneumonia risk among viral acute respiratory distress syndrome related or not to COVID 19 , 2021, Critical Care.

[6]  C. Lechiche,et al.  Performance of the RealStar® Pneumocystis jirovecii PCR kit for the diagnosis of Pneumocystis pneumonia , 2021, Mycoses.

[7]  O. Matos,et al.  Pneumocystis pneumonia in the COVID-19 pandemic era: similarities and challenges , 2021, Trends in Parasitology.

[8]  S. Ménard,et al.  Immune Response in Pneumocystis Infections According to the Host Immune System Status , 2021, Journal of fungi.

[9]  F. Schneider,et al.  Detection of Pneumocystis jirovecii in Patients with Severe COVID-19: Diagnostic and Therapeutic Challenges , 2021, Journal of fungi.

[10]  Guohui Fan,et al.  Risk Factors of Mortality From Pneumocystis Pneumonia in Non-HIV Patients: A Meta-Analysis , 2021, Frontiers in Public Health.

[11]  B. Saha,et al.  Narrative review of the relationship between COVID-19 and PJP: does it represent coinfection or colonization? , 2021, Infection.

[12]  Jing Xie,et al.  Lymphocyte subset analysis to evaluate the prognosis of HIV-negative patients with pneumocystis pneumonia , 2021, BMC Infectious Diseases.

[13]  N. Safdar,et al.  Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis , 2021, PloS one.

[14]  C. Feldman,et al.  The role of co-infections and secondary infections in patients with COVID-19 , 2021, Pneumonia.

[15]  Cecilia Lau,et al.  Pneumocystis jirovecii: a review with a focus on prevention and treatment , 2021, Expert opinion on pharmacotherapy.

[16]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[17]  A. Laghi,et al.  Differential diagnoses of COVID-19 pneumonia: the current challenge for the radiologist—a pictorial essay , 2021, Insights into Imaging.

[18]  J. Jarvis,et al.  The prevalence of laboratory-confirmed Pneumocystis jirovecii in HIV-infected adults in Africa: A systematic review and meta-analysis. , 2021, Medical mycology.

[19]  F. Noorbakhsh,et al.  Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview , 2021, International Immunopharmacology.

[20]  J. Parr,et al.  Pneumocystis and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection: A Case Report and Review of an Emerging Diagnostic Dilemma , 2020, Open forum infectious diseases.

[21]  B. Mégarbane,et al.  The presence of Pneumocystis jirovecii in critically ill patients with COVID-19 , 2020, Journal of Infection.

[22]  H. Badali,et al.  Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from Iran , 2020, Mycopathologia.

[23]  C. S. Wong,et al.  It’s not all about COVID‐19: pneumocystis pneumonia in the era of a respiratory outbreak , 2020, Journal of the International AIDS Society.

[24]  Zhenguo Liu,et al.  Bacterial and fungal infections in COVID-19 patients: A matter of concern , 2020, Infection Control & Hospital Epidemiology.

[25]  N. Shah,et al.  Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens. , 2020, JAMA.

[26]  B. Mégarbane,et al.  Do COVID-19 patients admitted to the ICU require anti-Pneumocystis jirovecii prophylaxis? , 2020, medRxiv.

[27]  J. Fishman,et al.  Pneumocystis jiroveci , 2020, Seminars in Respiratory and Critical Care Medicine.

[28]  M. Falavigna,et al.  How are systematic reviews of prevalence conducted? A methodological study , 2020, BMC Medical Research Methodology.

[29]  Ying-hao Wen,et al.  Diagnosis of Pneumocystis pneumonia by real-time PCR in patients with various underlying diseases. , 2020, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[30]  S. Bretagne,et al.  Outbreak-Causing Fungi: Pneumocystis jirovecii , 2019, Mycopathologia.

[31]  J. Guerrero,et al.  Changing Trends in the Epidemiology and Risk Factors of Pneumocystis Pneumonia in Spain , 2019, Front. Public Health.

[32]  Felipe García,et al.  Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients , 2019, Expert review of anti-infective therapy.

[33]  D. Beuningen,et al.  Influenza virus and factors that are associated with ICU admission, pulmonary co-infections and ICU mortality , 2018, Journal of Critical Care.

[34]  S. Secoli,et al.  The Joanna Briggs Institute approach for systematic reviews , 2018, Revista latino-americana de enfermagem.

[35]  Deepali Kumar,et al.  Cytomegalovirus infection and graft rejection as risk factors for pneumocystis pneumonia in solid organ transplant recipients: A systematic review and meta‐analysis , 2018, Clinical transplantation.

[36]  M. Hoenigl,et al.  Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia , 2018, Respiration.

[37]  A. Hashimoto,et al.  Incidence and Risk Factors for Infections Requiring Hospitalization, Including Pneumocystis Pneumonia, in Japanese Patients with Rheumatoid Arthritis , 2017, International journal of rheumatology.

[38]  S. Kohno,et al.  Adjunctive Corticosteroids for Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Patients: A Systematic Review and Meta-Analysis of Observational Studies , 2017 .

[39]  H. Einsele,et al.  ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. , 2016, The Journal of antimicrobial chemotherapy.

[40]  T. Boswell,et al.  Systematic review of outbreaks of Pneumocystis jirovecii pneumonia: evidence that P. jirovecii is a transmissible organism and the implications for healthcare infection control. , 2016, The Journal of hospital infection.

[41]  M. Mendelson,et al.  Burden of pneumocystis pneumonia in HIV-infected adults in sub-Saharan Africa: a systematic review and meta-analysis , 2016, BMC Infectious Diseases.

[42]  Ruoyu Li,et al.  Recent Advances in the Diagnosis of Pneumocystis Pneumonia. , 2016, Medical mycology journal.

[43]  M. Lazzerini,et al.  Risk Factors for Mortality from Acute Lower Respiratory Infections (ALRI) in Children under Five Years of Age in Low and Middle-Income Countries: A Systematic Review and Meta-Analysis of Observational Studies , 2015, PloS one.

[44]  Z. Munn,et al.  The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. , 2014, International journal of health policy and management.

[45]  G. Nichols,et al.  Increasing Pneumocystis Pneumonia, England, UK, 2000–2010 , 2013, Emerging infectious diseases.

[46]  F. Blyth,et al.  Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. , 2012, Journal of clinical epidemiology.

[47]  O. Lortholary,et al.  Pneumocystis jirovecii Pneumonia. , 2010, Infectious disease clinics of North America.

[48]  A. Ayadi,et al.  Molecular diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients , 2009, Mycoses.

[49]  Nick Freemantle,et al.  StatsDirect—Statistical Software for Medical Research in the 21st Century , 2000, BMJ : British Medical Journal.

[50]  P. Massip,et al.  High Frequency of Pneumocystis carinii sp.f. hominis Colonization in HIV‐Negative Patients , 1997, The Journal of eukaryotic microbiology.

[51]  W. Hughes,et al.  Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. , 1978, Pediatrics.